Background： The efficacy and safety evidence of bortezomib in multiple myeloma （MM） patients with hepatitis B is vacant.This study aimed to investigate the efficacy and safety of bortezomib in MM patients with hepa...Background： The efficacy and safety evidence of bortezomib in multiple myeloma （MM） patients with hepatitis B is vacant.This study aimed to investigate the efficacy and safety of bortezomib in MM patients with hepatitis B in China.Methods： From 2006 to 2011, 739 newly diagnosed MM patients were screened for serum hepatitis B virus （HBV） biomarkers.HBV-infected patients were followed for HBV reactivation by monitoring of serum alanine transaminase （ALT） and HBV DNA load.The pattern of HBV reactivation in relation to bortezomib was evaluated.Seven hundred thirty-nine MM patients were included in this study.Results： The prevalence of MM patients infected with HBV was 3.4% （n =25）, of which 17 cases were treated with bortezomib.Bortezomib had no significant influence on liver function （ALT before and after treatment： 36.69 ＆#177; 8.90 U/L vs.11.31 ＆#177; 2.74 U/L, P =0.19） and HBV DNA of MM patients with HBV （detectable HBV DNA percentage： 5.9% vs.11.8%, P =0.12）.Conclusions： Bortezomib can be used safely and effectively in MM patients with hepatitis B.HBV prophylaxis and surveillance are recommended during the MM treatment.展开更多
文摘Background： The efficacy and safety evidence of bortezomib in multiple myeloma （MM） patients with hepatitis B is vacant.This study aimed to investigate the efficacy and safety of bortezomib in MM patients with hepatitis B in China.Methods： From 2006 to 2011, 739 newly diagnosed MM patients were screened for serum hepatitis B virus （HBV） biomarkers.HBV-infected patients were followed for HBV reactivation by monitoring of serum alanine transaminase （ALT） and HBV DNA load.The pattern of HBV reactivation in relation to bortezomib was evaluated.Seven hundred thirty-nine MM patients were included in this study.Results： The prevalence of MM patients infected with HBV was 3.4% （n =25）, of which 17 cases were treated with bortezomib.Bortezomib had no significant influence on liver function （ALT before and after treatment： 36.69 ＆#177; 8.90 U/L vs.11.31 ＆#177; 2.74 U/L, P =0.19） and HBV DNA of MM patients with HBV （detectable HBV DNA percentage： 5.9% vs.11.8%, P =0.12）.Conclusions： Bortezomib can be used safely and effectively in MM patients with hepatitis B.HBV prophylaxis and surveillance are recommended during the MM treatment.
